Clinical Trial Update: INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs [Phase 2]

View source ↗

Summary

Phase 2 trial comparing INCB028050 to background therapy in active rheumatoid arthritis patients with inadequate response to conventional DMARDs; results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• INCB028050

Snippet

Sponsor: Incyte Corporation | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2018-09-04